How to Slow Down Aging? 10 Ways With the Best Scientific Evidence

Biological aging isn't a single disease with one mechanism and one drug — it's a collection of more than a dozen interconnected cellular and molecular processes, described in the scientific literature as the so-called hallmarks of aging: telomere shortening, accumulation of senescent cells, mitochondrial dysfunction, chronic low-grade inflammation, and several others, which we cover in more detail in separate knowledge-base entries. This fundamentally complicates the question "what slows down aging," because different interventions act on different mechanisms, to different degrees, and with very different quality of evidence.

The second problem is more practical: the strongest possible evidence for slowing aging — extending median lifespan in a randomized clinical trial in humans — is in practice nearly impossible to obtain. Such a trial would need to run for decades, involve thousands of participants, and account for a hard endpoint (death), which, given the realities of clinical research funding and ethics, happens exceptionally rarely. That's why the vast majority of "longevity evidence" rests either on observational studies in humans (correlation, not proof of causation) or on experiments in animal models (mice, fruit flies, roundworms) that live short enough for researchers to measure an effect across their whole lifespan — but that don't necessarily translate directly to humans.

In this article, for each of the ten ways, we clearly state which level of evidence it stands on: whether we have data from a randomized human trial with a hard or at least intermediate endpoint, observational human data, or — which applies to a good share of popular "longevity supplements" — mainly data from animal models, which are promising but don't yet constitute proof in humans.

Calorie restriction without malnutrition is the best-studied lifespan-extending intervention in model organisms — from yeast, through roundworms and fruit flies, to rodents, where the effect has been replicated for decades across hundreds of independent experiments. For years, though, the question remained whether a similar effect could even be safely and ethically tested in humans in a controlled study — and, if so, whether it would translate into measurable improvement in health markers, not just weight loss.

Instead of counting calories, you can reach for an overall eating pattern that, in meta-analyses covering millions of participants, consistently correlates with lower all-cause mortality — not just cardiovascular mortality. The Mediterranean diet is today probably the best-studied eating pattern in the context of longevity of all the available options.

The largest available meta-analysis (Sofi et al., over 4.17 million participants) showed that every 2-point increase in adherence to this diet is linked to an 8% lower risk of death from any cause, and a separate study in older adults confirmed the effect persists even after age 65. We describe the full numbers from both studies, including an honest discussion of why this is still observational data rather than a fully randomized proof of causation, in our article on the Mediterranean diet and longevity.

For years coffee had a reputation as a drink that burdens the heart, and today large, long-running cohort studies show the opposite picture — moderate, regular consumption (2-4 cups a day) consistently correlates with lower, not higher, risk of death from any cause, across many independent populations and research methodologies.

A cohort of over 185,000 people followed for an average of 16 years showed an 18% lower risk of death at 2-3 cups a day relative to no coffee consumption, and the effect was similar for caffeinated and decaffeinated coffee, suggesting that caffeine alone doesn't account for the whole association. We cover the full data, including an explanation of why the benefit doesn't keep growing endlessly with the amount of coffee drunk, in our article on coffee and longevity.

Sleep rarely makes it onto "longevity biohacking" lists alongside flashier topics like fasting or supplementation, even though it's one of the few everyday behaviors for which large cohort studies directly link it to all-cause mortality. The relationship has a U shape — both chronically too little sleep (under 6 hours) and too much sleep (over 9 hours) are linked to a higher risk of death than moderate sleep duration.

A surprising discovery from recent years, based on objective actigraphy measurements in over 60,000 people from the UK Biobank, found that the regularity of sleep timing is an even stronger predictor of all-cause mortality than total hours slept. You'll find the full description of this study, along with concrete, studied techniques for stabilizing your sleep rhythm (morning light, a safe caffeine cutoff window, alcohol's effect on sleep architecture), in our article on sleep biohacking and longevity, and a more practical, step-by-step guide in our article on how to improve sleep quality.

The "longevity" supplement shelf is one of the areas where the gap between marketing and hard clinical evidence is widest. Large, randomized trials on hard endpoints have shown an honest, if less flashy, picture: vitamins like D3 or B12 have solid evidence in their favor — but almost exclusively as correction of an actual, detected deficiency, not as a universal "boost" for someone with a normal level. High-dose antioxidant vitamins (beta-carotene, vitamin E), meanwhile, come with something worse than a lack of evidence — a documented signal of harm in certain populations from large trials.

Even a large, modern study of 390,000 participants followed for up to 27 years found no association between daily use of an ordinary multivitamin and lower mortality in people without diagnosed deficiencies. We cover the full evidence rundown for individual vitamins, including an honest accounting of the VITAL trial for vitamin D3 and omega-3, in our article on vitamins for longevity.

Intermittent fasting (restricting the time window for eating) has gained enormous popularity partly through its association with autophagy — the intracellular "cleanup" process for damaged proteins and organelles, for whose discovery Yoshinori Ohsumi received the Nobel Prize in 2016. The mechanism is well documented at the cell-biology level: a state of energy deficit inhibits the mTOR kinase and activates AMPK, which unlocks autophagy — we cover this in detail in our knowledge-base entry on autophagy.

Practical takeaway: intermittent fasting makes sense as a metabolic tool with real, if moderate, benefits in humans, and the autophagy mechanism gives it credible biological grounding — but claiming that a specific number of fasting hours "guarantees" autophagy activation in humans to a degree comparable to what's observed in mouse experiments goes beyond what's known with certainty today. People with type 1 diabetes, who are pregnant, breastfeeding, or have a history of eating disorders should avoid intermittent fasting without first consulting a doctor.

Regular physical activity affects aging through many parallel pathways at once — it improves cardiovascular fitness, insulin sensitivity, bone density, and, as newer meta-analyses show, is also linked to longer telomeres in active people relative to sedentary ones. A less obvious but very well-documented element of this picture is muscular strength itself, most simply measured as grip strength — a simple, cheap measurement that has proven to be a surprisingly strong predictor of survival in very large population studies.

Inflammaging — a term coined in 2000 by Claudio Franceschi based on research into centenarians — describes the chronic, low-grade, body-wide inflammation that builds up with age even without an active infection, today recognized as one of the fundamental mechanisms linking aging to age-related diseases: atherosclerosis, insulin resistance, sarcopenia, and neurodegeneration. We describe the full mechanism — accumulation of senescent cells secreting SASP, increased intestinal permeability, release of DAMP signals — in our knowledge-base entry on inflammaging.

For years, inflammaging remained largely a descriptive concept, supported by correlations between inflammatory markers (hsCRP, IL-6) and risk of age-related disease. A large clinical trial from recent years, however, provided direct, causal evidence that lowering inflammation itself — independent of cholesterol — genuinely reduces the risk of cardiovascular events in humans.

Mitochondria, responsible for producing cellular energy, accumulate damage to their own DNA with age and lose efficiency — this is one of the commonly listed hallmarks of cellular aging. The cell removes the most damaged mitochondria through a process called mitophagy (a selective subtype of autophagy, described in detail in our knowledge-base entry on mitophagy), and the efficiency of this mitochondrial quality-control mechanism naturally declines with age.

Directly measuring mitophagy in a living human remains largely experimental, so — similar to autophagy in general in point 6 — evidence for stimulating it comes mainly from cellular and animal models. The practical takeaways, however, are well documented independent of the difficulty of direct measurement: regular aerobic activity (described in point 7) stimulates the biogenesis of new, healthier mitochondria in muscle in animal studies and, partially, in humans, and fasting and calorie restriction (points 1 and 6) are linked in animal models to enhanced mitophagy that removes damaged organelles.

Three substances come up most often in discussions of pharmacologically slowing aging: metformin (an antidiabetic drug used for decades, also studied off-label), rapamycin (an immunosuppressant that inhibits the mTOR kinase), and NMN (an NAD+ precursor available as an over-the-counter supplement). Each has a different, but still incomplete, evidentiary status — and none has, to date, a completed, large clinical trial in humans with a hard endpoint of extended lifespan.

Rapamycin has the strongest evidence of the three, but almost exclusively in animals — it consistently extends the lifespan of mice in the multi-year, multi-center Interventions Testing Program funded by the American National Institute on Aging, even when administered to animals already at an older age. In humans, rapamycin is approved as an immunosuppressant drug (used, among other things, after organ transplants) with real, serious side effects with chronic use, and its potential use at lower, "anti-aging" doses in healthy people remains the subject of early research, not established clinical practice.

Metformin has large clinical trials in diabetics behind it, showing a favorable safety profile and some observational signals (lower mortality in diabetics on metformin relative to some comparison groups) suggesting a potential effect beyond glycemic control alone — hence the TAME trial (Targeting Aging with Metformin), designed specifically for this purpose, testing metformin in non-diabetics for delaying age-related multimorbidity. TAME's results still aren't available, so as of today, healthy people using metformin solely to slow aging is a decision based on extrapolation from observational data in diabetics, not on a completed trial designed around longevity in healthy people. Metformin is also linked to a documented risk of lowering vitamin B12 levels with long-term use, which we describe in detail in a separate article.

If we had to prioritize among these ten, we'd pick the ways with the strongest direct human evidence and the lowest risk: the Mediterranean diet or moderate calorie restriction, regular physical activity including strength training (not just aerobic), good, regular sleep, and, for many people, simply not changing your coffee-drinking habit out of health worry. These four have solid direct human data, low risk, and, importantly, reinforce each other — good sleep makes it easier to stick to diet and training, and regular activity improves sleep quality.

Intermittent fasting, inflammation control, and mitochondrial health have solid biological rationale but largely still await full confirmation in humans — worth treating as a sensible, probably beneficial supplement, not a foundation of a strategy. Experimental longevity drugs remain today an area of active research, not a ready-made prescription — a more honest, if less exciting, answer than what a good part of the supplement and biohacking market promises.